Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Younossi, 2011, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, 524, 10.1016/j.cgh.2011.03.020 Das, 2010, Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease, Hepatology, 51, 1593, 10.1002/hep.23567 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127 Brunt, 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 809, 10.1002/hep.22724 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 10.1053/j.gastro.2015.04.043 Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002/hep.24268 Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology, Gastroenterology, 142, 1592, 10.1053/j.gastro.2012.04.001 Bravo, 2001, Liver biopsy, N Engl J Med, 344, 495, 10.1056/NEJM200102153440706 Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014 Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623 Boursier, 2012, Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice, Expert Opin Med Diagn, 6, 381, 10.1517/17530059.2012.691878 Degos, 2010, Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study), J Hepatol, 53, 1013, 10.1016/j.jhep.2010.05.035 Zarski, 2012, Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study, J Hepatol, 56, 55, 10.1016/j.jhep.2011.05.024 2015, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Angulo, 2013, Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 145, 10.1053/j.gastro.2013.06.057 Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156 Harrison, 2008, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease, Gut, 57, 1441, 10.1136/gut.2007.146019 Cales, 2009, Comparison of blood tests for liver fibrosis specific or not to NAFLD, J Hepatol, 50, 165, 10.1016/j.jhep.2008.07.035 Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 Imbert-Bismut, 2001, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, Lancet, 357, 1069, 10.1016/S0140-6736(00)04258-6 Adams, 2005, Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection, Clin Chem, 51, 1867, 10.1373/clinchem.2005.048389 Calès, 2005, A novel panel of blood markers to assess the degree of liver fibrosis, Hepatology, 42, 1373, 10.1002/hep.20935 Cales, 2008, Reproducibility of blood tests of liver fibrosis in clinical practice, Clin Biochem, 41, 10, 10.1016/j.clinbiochem.2007.08.009 Castera, 2008, Non-invasive evaluation of liver fibrosis using transient elastography, J Hepatol, 48, 835, 10.1016/j.jhep.2008.02.008 Boursier, 2013, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, 57, 1182, 10.1002/hep.25993 Schwabl, 2015, New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension, Liver Int, 35, 381, 10.1111/liv.12623 Lambert, 2008, How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited, Clin Chem, 54, 1372, 10.1373/clinchem.2007.097923 Boursier, 2014, Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C, Aliment Pharmacol Ther, 40, 178, 10.1111/apt.12813 Boursier, 2015, An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards, J Hepatol, 62, 807, 10.1016/j.jhep.2014.10.042 Boursier, 2011, Comparison of accuracy of fibrosis degree classifications by liver biospy and non invasive tests in chronic hepatitis C, BMC Gastroenterol, 30, 132, 10.1186/1471-230X-11-132 Boursier, 2012, Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely non-invasive, Hepatology, 55, 58, 10.1002/hep.24654 Poynard, 2004, Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C, Comp Hepatol, 3, 8, 10.1186/1476-5926-3-8 de Ledinghen, 2012, Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R), J Hepatol, 56, 833, 10.1016/j.jhep.2011.10.017 Myers, 2012, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 2012, 199, 10.1002/hep.24624 Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038/ajg.2012.331 Afdhal, 2004, Evaluation of liver fibrosis: a concise review, Am J Gastroenterol, 99, 1160, 10.1111/j.1572-0241.2004.30110.x Guha, 2006, Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease, Gut, 55, 1650, 10.1136/gut.2006.091454 Sebastiani, 2015, Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis, PLoS One, 10, 10.1371/journal.pone.0128774 Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 Armstrong, 2014, Extrahepatic complications of nonalcoholic fatty liver disease, Hepatology, 59, 1174, 10.1002/hep.26717 Lade, 2014, Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer, Curr Opin Oncol, 26, 100, 10.1097/CCO.0000000000000042